Can a Two-Drug attack shrink Hard-to-Treat breast cancer?

NCT ID NCT07757230

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This phase II trial is testing whether combining an experimental antibody called SSGJ-612 with a targeted chemotherapy (an antibody-drug conjugate) can shrink tumors in people with hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer. The study enrolls about 87 participants whose cancer has spread and who have not previously tested positive for HER2. The main goal is to see how many patients experience tumor shrinkage, while also monitoring side effects and how long the benefit lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SSGJ-612 (an experimental HER2-targeted antibody) combined with a HER2-targeted antibody-drug conjugate (ADC)
What this could lead to
If successful, this combination could offer a new treatment option for people with HR-positive, HER2-low or ultralow metastatic breast cancer, potentially improving tumor shrinkage and delaying progression.
What could go wrong
This is a phase II trial with a modest number of participants, so results may not hold up in larger studies. The combination may cause side effects, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.